CHCWM – Cancer & Hematology Centers of West Michigan

LOXO-RET-17001 (Loxo Pharmaceuticals)

Description:  Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and other Tumors with Increased RET Activity.

Mechanism of Action:  very potent RET inhibitor

Target Patient Population:  Any advanced solid tumors, particularly those with known RET Gene alteration (NSCLC with RET fusions, Medullary thyroid cancer or other tumor types with RET alterations considered pathogenic)

Study Design:  Drug is to be taken orally BID.